bioAffinity Technologies (BIAF) announced a collaboration with Pictor to integrate their respective technologies for developing next-generation diagnostic tests for asthma and COPD. This partnership aims to improve personalized treatment by analyzing immune cell populations and cytokine profiles related to airway inflammation, potentially increasing laboratory throughput and reducing costs.
bioAffinity Technologies (BIAF) has entered a collaboration with Pictor, Inc. to combine their expertise in flow cytometry and targeted proteomic analysis. This partnership is focused on developing advanced diagnostic tests for asthma and COPD, aiming to provide more personalized and effective treatments by analyzing specific inflammatory profiles. This is a positive development for BIAF as it expands its diagnostic pipeline and addresses a significant global market for respiratory diseases. In the short term, this could generate investor interest in BIAF due to the potential for new product development and market expansion. Long-term, the success of these diagnostic tests could significantly impact BIAF's revenue and market position in the diagnostics sector, offering a key opportunity for growth in a market projected to exceed $155 billion by 2030.